CClinicalTrials.gg
TerminatedNCT05751772EDUC-ICUpdated Mar 26, 2024

Improving Knowledge in Heart Failure Inpatient With Therapeutic Education

An interventional study of Patient therapeutic education in Heart Failure With Reduced Ejection Fraction, Heart Failure; With Decompensation and Pharmacist-Patient Relations, sponsored by University Hospital, Geneva. Terminated at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-26.

Sponsored by University Hospital, Geneva · Not applicable, Interventional, and Health services research

Why this study was terminated
Difficulty in recruiting and lack of resources
Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective is to evaluate the impact of a pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients. The knowledge score on heart failure disease and medications will be compared between two groups one month after hospitalization. The intervention group will receive a therapeutic education intervention and usual hospital care and the control group will receive only usual hospital care.

Read the detailed description

Heart failure patients are at risk of decompensation of their disease and frequent hospitalizations. Poor adherence to their treatment may be the cause. By improving the knowledge of hospitalized heart failure patients about their disease and their medications, it is expected that these patients will adhere better to their heart failure drug therapy and benefit from a better effectiveness of their treatment. This could promote an improvement in their quality of life, a decrease in their risk of disease complications and even an increase in their life expectancy.

The objective of this research project is to deploy a therapeutic teaching intervention at the bedside of decompensated and hospitalized heart failure patients, associated with follow-up by the pharmacist at discharge from the hospital, and to measure its impact on knowledge change (primary endpoint), on their beliefs about medications, on their therapeutic adherence, and on the consumption of unplanned care such as rehospitalizations and emergency room visits (secondary endpoints).

02

Conditions studied

  • Heart Failure With Reduced Ejection Fraction
  • Heart Failure; With Decompensation
  • Pharmacist-Patient Relations
  • Medication Adherence
  • Knowledge, Attitudes, Practice

Browse trials for

Keywords

  • patient therapeutic education
  • clinical pharmacy
  • pharmaceutical care
03

In context

Heart Failure

5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.

This study's enrollment of 38 is below the median of 72 across 3,736 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

University Hospital, Geneva is the lead sponsor of 372 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Hospitalization in the Department of General Internal Medicine or Cardiology for decompensated heart failure with lowered left ventricular ejection fraction (LVEF) (≤40%) from any cause or mildly lowered LVEF (41-49%) with the presence of heart failure-specific drug therapy
  • Stability of the patient's clinical condition
  • ≥ 2 heart failure medications
  • ≥18 years
  • Full capacity of discernment
  • Absence of cognitive impairment
  • Ability to speak, understand and read in French
  • Get a personal telephone
  • Consent form signed by the participant

Exclusion criteria

Exclusion Criteria:

  • Inability to follow study procedures
  • Institutionalized persons
  • Asylum seekers, homeless people, prisoners
  • Incapacity of judgment and discernment
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    "Patient therapeutic education" group

    The intervention group will benefit from a pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients and usual hospital care (medical and nursing care)

    Other: Patient therapeutic education

  • No intervention
    "Usual hospital care" group

    The control group do only benefit from the usual hospital care (any medical and nursing care giving to an acute heart failure inpatient) and won't benefit from the pharmacist's educational intervention.

Interventions

  • OtherPatient therapeutic education

    The pharmacist-led therapeutic education intervention on the knowledge of hospitalized heart failure patients is made by a clinical pharmacist and includes: 1. Targeted education on patient needs related to heart failure, heart failure medications and self-care; 2. a pre-discharge interview to consolidate key teaching messages and prepare the patient for their discharge treatment plan; 3. a telephone call the week of discharge to ensure pharmaceutical follow-up between hospital care and return home (continuity of care, transition of care).

    Also known as: inpatient therapeutic education interview and outpatient pharmaceutical follow-up

06

What researchers measure

Primary outcomes

  1. Change in knowledge score

    Patients' level of knowledge about their disease and heart failure medications before the educational pharmaceutical intervention (pre-test) and immediately after the intervention (post-test n° 1) for the intervention group , as well as at 1 month after hospital discharge (post-test n°2) for the intervention and control group. It will be measured by means of a 17-question questionnaire specifically developed for this project. This level is valued by a minimum score of 0 points and a maximum of 17 points. Higher score means a better level of knowledge. The positive difference between pre-test and post-tes means an increase in knowledge and a negative difference means a decrease in knowledge.

    Time frame: at the baseline time (zero time), immediately after therapeutic education intervention and 30 days after hospital discharge

Secondary outcomes

  1. Change in Beliefs about medicines Score

    Beliefs about medicines will be measured via the specific Beliefs about Medicines Questionnaire (BMQs) score at baseline time (at the inclusion time)(pretest) and at 1 month after hospital discharge (post-test) in both groups. Scores range from 5 to 25 points for both subscales. The higher the score for the specific need, the more it means that the patient has a strong perception that he needs the drugs to be healthy and live. For specific concerns, the higher the score, the more the patient is concerned about a potential negative effect of taking the medication. A third score can be calculated by subtracting specific concerns from specific needs. This gives a score of -20 to +20. A positive value means that the need for the treatment exceeds the concerns of taking it.

    Time frame: at the baseline time (zero time),30 days after hospital discharge

  2. Change in Medication Adherence Score

    Adherence will be assessed with the Three Item Self Report Scale at baseline time (at the inclusion time) (pre-test) and at 1 month after hospital discharge (post-test) in both groups. This questionnaire consists of 3 questions; one which evaluates the number of days of forgetting to take medication over the last month, one which evaluates the frequency of taking medication according to medical prescription and the third which makes it possible to measure the level of competence in the correct taking of medication that takes ownership of the patient. Responses are converted on a scale of 0 to 100 (0 is the lowest adherence and 100 the highest). An average of the three answers is used to assign the adhesion score. Higher the score is, better the adherence is.

    Time frame: at the baseline time (zero time),30 days after hospital discharge

  3. Level of satisfaction on therapeutic education

    Patient satisfaction will be assessed using a 13-questions questionnaire specifically developed for this project, after the education interview to assess the usefulness and quality of the teaching intervention. There is no score related to the questionnaire. This qualitative assessment will allow us to determine whether this new intervention should be continued and to identify its strengths and weaknesses.

    Time frame: immediately after therapeutic education intervention

  4. Rehospitalization or emergency room visits

    The rate of rehospitalization or emergency room visits will be evaluated during the telephone call made by a research assistant at D30 post hospital discharge. The cause of hospitalization will be determined by means of the computerized hospital patient file if he is rehospitalized at the university hospital of Geneva (HUG) or directly to the patient (or his attending physician depending) if he is hospitalized in another hospital. It is interesting to assess whether the patient consumed unplanned care and whether it was related to instability of his heart failure.

    Time frame: 30 days after hospital discharge

  5. Death at 1 month after discharge

    The mortality rate will be assessed in both groups. This information can be collected from the participants' computerized patient records if mentioned or from the participants' relatives or attending physician.

    Time frame: 30 days after hospital discharge

  6. Patient experiment and feeling after discharge

    The patient's experience and feelings upon returning home will be assessed during a telephone call between D3 and D7 after the patient's discharge from the hospital with open questions (no validated questionnaire is used). The objective will be to identify the patient's needs, their feelings about going home, what they liked, what they missed to readjust the counseling to the patient.

    Time frame: 7 days after hospital discharge

  7. CardioMeds app usability

    Use and usability of the mobile smartphone application (CardioMeds® ) will be explored by the research assistant during the telephone call at D30 post hospital discharge using a validated standardized questionnaire (System Usability Scale = SUS). SUS gives a single score representing a measure composite of the general user-friendliness of the studied service. The score ranges from 0 to 100.It is generally considered that a score is "good" from 75, fair or fair between 50 and 75. A score below 50 reveals major problems in terms of customer satisfaction.

    Time frame: 30 days after hospital discharge

  8. Self-Care of Heart Failure Index

    Self-care skills of patients using CardioMeds® will be explored using a validated score, the Self-Care of Heart Failure Index composed of 22 questions to measure the effect of this application on patients' level of empowerment in their care. The scale is subdivided in three measurement : maintenance score, management score and self-care confidence score. Each scale score is standardized to a 0 to 100 range. A score of ≥70 can be used as the cut-point to judge self-care adequacy,

    Time frame: 30 days after hospital discharge

  9. Level of satisfaction on global pharmaceutical care

    This second satisfaction questionnaire consisting of 8 questions specifically developed for this project, will be sent at 1 month after hospital discharge to assess the patient's overall satisfaction with the pharmaceutical care follow-up provided. There is no score related to the questionnaire. This qualitative assessment will allow us to determine whether the hospital pharmaceutical care

    Time frame: 30 days after hospital discharge

07

Study locations

1 site
  • University Hospital of Geneva
    Geneva, 1205, Switzerland
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Jul 22, 2022
  • Informed consent form · Jul 22, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Individual participant data (original data sets) that underlie the results reported in published articles, after deidentification (text, tables, figures, and appendices).

Supporting information: Study protocol

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05751772
Lead sponsor
University Hospital, Geneva
Collaborators
Vifor Pharma, Labatec Pharma SA, Bayer, AstraZeneca
Responsible party
Mégane Jermini (Hospital and Clinical Pharmacist, pharmD, Principal Investigator, University Hospital, Geneva) — Principal investigator
First posted
Mar 2, 2023
Start date
Dec 13, 2022
Primary completion
Jan 31, 2024
Completion
Jan 31, 2024
Last update
Mar 26, 2024

Study contacts

Pascal Bonnabry, Professor
study director · University of Geneva

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion